ZymoGenetics Inc. Press Release Published: 02 June 10 ZymoGenetics, Inc. (NASDAQ: ZGEN) today announced the start of the second part of a clinical trial Phase 2 with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic diseases have hepatitis C virus (HCV).
Could this be the easy answer to your health problems?